<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Gonorrhoea – Quick Reference</title>
<meta name="viewport" content="width=device-width, initial-scale=1">
<style>
:root{
  --nice-blue:#005eb8;
  --nice-light:#f3f8ff;
  --nice-grey:#f5f5f5;
  --text:#222;
  --shadow:0 2px 6px rgba(0,0,0,.08);
}
*{box-sizing:border-box;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Helvetica,Arial,sans-serif}
body{margin:0;padding:0;background:#fff;color:var(--text)}
header{
  background:linear-gradient(135deg,var(--nice-blue),#0072ce);
  color:#fff;
  padding:2rem 1rem;
  text-align:center;
  box-shadow:var(--shadow)
}
h1{margin:0;font-size:1.6rem;font-weight:600}
main{max-width:900px;margin:2rem auto;padding:0 1rem}
h2{color:var(--nice-blue);border-bottom:2px solid var(--nice-light);padding-bottom:.3rem;margin-top:2rem;font-size:1.2rem}
ul{margin:0 0 1rem 1.2rem;padding:0}
li{line-height:1.5}
table{width:100%;border-collapse:collapse;margin:1rem 0}
th,td{padding:.6rem;text-align:left;border-bottom:1px solid var(--nice-grey)}
th{background:var(--nice-light);font-weight:600}
.card{background:#fff;border:1px solid var(--nice-grey);border-radius:8px;padding:1rem;margin-bottom:1rem;box-shadow:var(--shadow)}
.flowchart{background:var(--nice-light);padding:1rem;border-radius:8px;font-family:monospace;font-size:.9rem;white-space:pre-wrap;overflow-x:auto}
footer{margin:3rem 0;text-align:center;font-size:.8rem;color:#666}
@media(max-width:600px){
  h1{font-size:1.35rem}
  th,td{padding:.5rem;font-size:.9rem}
}
</style>
</head>
<body>

<header>
  <h1>Gonorrhoea – Quick Reference (June 2025)</h1>
</header>

<main>

  <!-- Suspect -->
  <section class="card">
    <h2>1. Suspect</h2>
    <ul>
      <li><strong>Men:</strong> mucopurulent urethral discharge, dysuria (90 % symptomatic).</li>
      <li><strong>Women:</strong> altered vaginal discharge, dysuria, lower abdominal pain (≈50 % symptomatic).</li>
      <li><strong>Risk factors:</strong> 15–24 yrs | MSM | multiple partners | prior STI | black Caribbean ethnicity | deprivation.</li>
    </ul>
  </section>

  <!-- 60-second Assessment -->
  <section class="card">
    <h2>2. 60-second Assessment</h2>
    <table>
      <tr><th>Step</th><th>Action</th></tr>
      <tr><td><strong>History</strong></td><td>Symptoms, sexual contacts & practices, condom use, STI/HIV history.</td></tr>
      <tr><td><strong>Exam</strong></td><td>• Men – penis, testes, epididymis.<br>• Women – speculum & bimanual for PID.<br>• All – pharynx, rectum, eyes.</td></tr>
      <tr><td><strong>Red flags</strong></td><td>Fever, joint pain/swelling, rash (DGI); severe pelvic pain (PID).</td></tr>
    </table>
  </section>

  <!-- Test & Confirm -->
  <section class="card">
    <h2>3. Test & Confirm</h2>
    <table>
      <tr><th>Site</th><th>Test</th></tr>
      <tr><td>Anogenital</td><td>NAAT + culture for susceptibility</td></tr>
      <tr><td>MSM</td><td>Add routine rectal NAAT</td></tr>
      <tr><td>All with urogenital gonorrhoea</td><td>Pharyngeal NAAT</td></tr>
    </table>
    <p><em>Children &lt;13 yr or safeguarding concerns → refer to social care.</em></p>
  </section>

  <!-- Management Flowchart -->
  <section class="card">
    <h2>4. Immediate Management Algorithm</h2>
    <div class="flowchart">┌─ Confirmed gonorrhoea ─┐
│                       │
│   ┌───────────────────┴───────────────────┐
│   │ Can attend GUM clinic?                │
│   └─────┬─────────────────────┬───────────┘
│         │ Yes                 │ No / declined
│         ▼                     ▼
│   Refer to GUM / SHS     Treat in primary care
│                               │
│                               ├─ Ceftriaxone 1 g IM single dose
│                               │
│                               └─ Allergy / IM contraindicated
│                                  ├─ Gentamicin 240 mg IM + Azithro 2 g PO
│                                  ├─ Cefixime 400 mg PO ×2 6-12 h apart + Azithro 2 g PO
│                                  └─ Azithro 2 g PO (only if susceptible isolate)
└───────────────────────────────────────────────</div>
  </section>

  <!-- Partner Rx & Follow-Up -->
  <section class="card">
    <h2>5. Partner Rx & Follow-Up</h2>
    <ul>
      <li><strong>Notify partners:</strong> symptomatic urethral men → 2 weeks | all others → 3 months.</li>
      <li><strong>Empirical Rx contacts</strong> within 14 days of exposure.</li>
      <li><strong>Follow-up ≈ 1 week:</strong> TOC <em>not</em> required after ceftriaxone 1 g unless pharyngeal infection, resistance, or persistent symptoms.</li>
    </ul>
  </section>

  <!-- Counselling -->
  <section class="card">
    <h2>6. Key Counselling</h2>
    <ul>
      <li>Abstain from sex until 7 days after both partners treated.</li>
      <li>Screen for chlamydia, HIV, syphilis.</li>
      <li>Provide NHS patient leaflet & safer-sex advice.</li>
    </ul>
  </section>

  <!-- Admission -->
  <section class="card">
    <h2>7. Admission / Urgent Referral</h2>
    <ul>
      <li>Suspected disseminated gonorrhoea (DGI).</li>
      <li>Severe PID or conjunctival gonorrhoea.</li>
      <li>Treatment failure or antibiotic allergy.</li>
    </ul>
  </section>

</main>

<footer>
© NICE Clinical Knowledge Summaries – adapted for quick reference | Last revised June 2025
</footer>

</body>
</html>